Who is a Candidate for SPRAVATO®? Patient Eligibility and Considerations

For those struggling with severe depression, treatment options that go beyond traditional medications and therapies can offer new hope. SPRAVATO® (esketamine) nasal spray is a groundbreaking treatment designed for adults with treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation. Developed as an FDA-approved nasal spray, SPRAVATO® is administered under medical supervision to provide rapid relief when other antidepressant treatments fall short. At Thunder Pain and Wellness, we recognize the importance of understanding eligibility for this innovative treatment and aim to help our patients determine if SPRAVATO® could be an appropriate choice.

What is SPRAVATO®?

SPRAVATO® is a nasal spray that contains esketamine, a form of ketamine, which has shown rapid antidepressant effects in many cases. Unlike oral antidepressants that target neurotransmitters like serotonin or dopamine, SPRAVATO® acts primarily on glutamate receptors, which helps to establish new neural connections in the brain. This mechanism can bring relief faster than traditional medications, which can take weeks to show results. Patients administer SPRAVATO® under the guidance of a healthcare professional, making it a controlled yet accessible treatment for suitable candidates.
 

Who is a Candidate for SPRAVATO®?

While SPRAVATO® can be a powerful treatment option, it is not suitable for everyone. Here are the key considerations for potential candidates:
 

1. Diagnosis of Treatment-Resistant Depression (TRD)

Patients diagnosed with TRD are typically those who have tried at least two different oral antidepressants without significant improvement in their symptoms. SPRAVATO® may be considered as an option for individuals who have found little to no relief from traditional antidepressant medications.
 

2. Major Depressive Disorder (MDD) with Acute Suicidal Ideation

SPRAVATO® is also approved for adults with MDD who are experiencing acute suicidal thoughts or behaviors. It is designed to offer rapid relief in crisis situations, helping to alleviate severe symptoms and provide a foundation for further treatment.
 

3. Adults Aged 18 and Older

SPRAVATO® is FDA-approved for adults aged 18 and older. It has not been tested or approved for children or adolescents under the age of 18.
 

4. Not Suitable for Those with Certain Medical Conditions

Patients with specific medical or mental health conditions may not be suitable candidates for SPRAVATO®. Individuals with a history of certain heart conditions, high blood pressure that is uncontrolled, or recent substance use issues should discuss these factors with a healthcare provider. Due to the unique way SPRAVATO® interacts with the brain, it is essential that candidates be evaluated for any underlying conditions that could affect their response to treatment.
 

Important Considerations for SPRAVATO® Treatment

Once a candidate is deemed eligible, there are additional considerations regarding SPRAVATO® treatment that patients should keep in mind. SPRAVATO® is only administered in a certified healthcare facility due to the potential for side effects such as sedation, dissociation, or elevated blood pressure. Patients will be observed for a minimum of two hours after each session to ensure they are safe to return home.
 

Common side effects of SPRAVATO® include dizziness, nausea, increased blood pressure, and dissociation (a feeling of detachment from one’s body or surroundings). While these effects are generally short-lived, candidates need to be aware and discuss these with their provider before starting treatment.
 

SPRAVATO® is intended to be used in conjunction with an oral antidepressant, not as a standalone treatment. Candidates for SPRAVATO® should be prepared to continue their prescribed antidepressant medication alongside this therapy, as this combination has shown to improve long-term effectiveness.

SPRAVATO® requires a commitment to a structured treatment schedule, especially during the initial phases. The treatment protocol includes twice-weekly sessions for the first four weeks, then once a week for the following month. Candidates should ensure they can adhere to this schedule to receive the full benefit.
 

Is SPRAVATO® Right for You?

If you or someone you know has been battling treatment-resistant depression or severe depression with suicidal thoughts, SPRAVATO® may provide a new path to relief. We work closely with our patients to evaluate their unique needs, medical history, and mental health goals. A thorough assessment helps determine whether SPRAVATO® is the right fit and guides patients through a comprehensive treatment plan.

Reach out to Thunder Pain and Wellness to learn more about SPRAVATO® and explore whether this transformative treatment is an option for you. Visit our office in Reno, Nevada, or call (775) 254-7400 to schedule a consultation today.